Affimed NV logo

AFMD - Affimed NV Share Price

$3.85 0.0  1.0%

Last Trade - 10/08/20

Small Cap
Market Cap £244.8m
Enterprise Value £167.2m
Revenue £13.7m
Position in Universe 3363rd / 6393
Unlock AFMD Revenue
Relative Strength (%)
1m -21.7%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -22.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
3.38 7.56 6.31 2.01 23.7 21.4 19.7 41.4 +44.6%
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Affimed NV revenues decreased 55% to EUR5.1M. Net loss totaled EUR8.3M vs. income of EUR1.9M. Revenues reflect Collaboration revenue segment decrease of 54% to EUR4.9M, Service revenue segment decrease of 72% to EUR212K, United States segment decrease of 52% to EUR5.1M, Europe segment decrease of 100% to EUR2K. Net loss reflects Research and development expenses - Bala increase of 45% to EUR11.1M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for AFMD
Graphical History


AFMD Revenue Unlock AFMD Revenue

Net Income

AFMD Net Income Unlock AFMD Revenue

Normalised EPS

AFMD Normalised EPS Unlock AFMD Revenue

PE Ratio Range

AFMD PE Ratio Range Unlock AFMD Revenue

Dividend Yield Range

AFMD Dividend Yield Range Unlock AFMD Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
AFMD EPS Forecasts Unlock AFMD Revenue
Profile Summary

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.

Last Annual December 31st, 2019
Last Interim March 31st, 2020
Public Since September 12, 2014
No. of Shareholders: 6
No. of Employees: 128
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 83,849,901
Free Float (0.0%)
Eligible for
AFMD Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for AFMD
Upcoming Events for AFMD
Tuesday 11th August, 2020
Q2 2020 Affimed NV Earnings Call
Tuesday 11th August, 2020
Q2 2020 Affimed NV Earnings Release
Frequently Asked Questions for Affimed NV
What is the Affimed NV share price?

As of 10/08/20, shares in Affimed NV are trading at $3.85, giving the company a market capitalisation of £244.8m. This share price information is delayed by 15 minutes.

How has the Affimed NV share price performed this year?

Shares in Affimed NV are currently trading at $3.85 and the price has moved by 37.55% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Affimed NV price has moved by 19.86% over the past year.

What are the analyst and broker recommendations for Affimed NV?

Of the analysts with advisory recommendations for Affimed NV, there are there are currently 2 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Affimed NV is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Affimed NV next release its financial results?

Affimed NV is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Affimed NV dividend yield?

Affimed NV does not currently pay a dividend.

Does Affimed NV pay a dividend?

Affimed NV does not currently pay a dividend.

When does Affimed NV next pay dividends?

Affimed NV does not currently pay a dividend.

How do I buy Affimed NV shares?

To buy shares in Affimed NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Affimed NV?

Shares in Affimed NV are currently trading at $3.85, giving the company a market capitalisation of £244.8m.

Where are Affimed NV shares listed? Where are Affimed NV shares listed?

Here are the trading details for Affimed NV:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: AFMD
What kind of share is Affimed NV?

Based on an overall assessment of its quality, value and momentum, Affimed NV is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Affimed NV share price forecast 2020?

Shares in Affimed NV are currently priced at $3.85. At that level they are trading at 85.3% discount to the analyst consensus target price of 0.00.

Analysts covering Affimed NV currently have a consensus Earnings Per Share (EPS) forecast of -0.506 for the next financial year.

How can I tell whether the Affimed NV share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Affimed NV. Over the past six months, the relative strength of its shares against the market has been 43.36%. At the current price of $3.85, shares in Affimed NV are trading at 35.81% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Affimed NV PE Ratio?

We were not able to find PE ratio data for Affimed NV.

Who are the key directors of Affimed NV?

Affimed NV's management team is headed by:

Adi Hoess - CEO
Florian Fischer - CFO
Martin Treder - CSO
Wolfgang Fischer - COO
Leila Alland - MGB
Thomas Hecht - CSU
Ferdinand Verdonck - IND
Berndt Modig - IND
Richard Stead - SUB
Ulrich Grau - IND
Bernhard Ehmer - IND
Denise Mueller - PRE
Mathieu Simon - IND
Andreas Harstrick - MGB
Arndt Schottelius - CSO
Angus Smith - CFO
Who are the major shareholders of Affimed NV?

Here are the top five shareholders of Affimed NV based on the size of their shareholding:

New Enterprise Associates (NEA) Venture Capital
Percentage owned: 7.31% (6.13m shares)
Millennium Management LLC Hedge Fund
Percentage owned: 5.52% (4.63m shares)
Intracoastal Capital, L.L.C. Corporation
Percentage owned: 5.52% (4.63m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 4.81% (4.03m shares)
Stonepine Capital Management, LLC Investment Advisor/Hedge Fund
Percentage owned: 3.58% (3.00m shares)
Similar to AFMD
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.